IMW 2019 | Using transcription factors as therapeutic targets in MM
Raphael Szalat
• 14 Sep 2019
Dr. Raphael Szalat, MD, of the Dana-Farber Cancer Institute, Boston, MA, explains his research into the role of transcription factors such as MEF2C in multiple myeloma and the potential to use them as therapeutic targets. This was discussed at the International Myeloma Workshop (IMW) 2019, in Boston, MA.
